GS
MLTX icon

George Soros’s MoonLake Immunotherapeutics MLTX Stock Holding History

George Soros’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,000
Closed -$6.04M – 236
2023
Q4 		$6.04M Buy
100,000
+44,000
+79% +$2.27M 0.08% 151
2023
Q3 		$3.19M Buy
+56,000
New +$3.09M 0.05% 179

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

George Soros's MLTX Position: Q1 2024 in Review

George Soros sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2024, closing a stake of 100,000 shares — an estimated $6.04M sold.

George Soros first reported a position in MLTX in Q3 2023 and held it in 2 quarters. The position peaked at $6.04M in Q4 2023. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • George Soros reported no remaining MoonLake Immunotherapeutics position as of Q1 2024 after selling out during the quarter.
  • George Soros sold 100,000 MoonLake Immunotherapeutics shares in Q1 2024, an estimated $6.04M.
  • George Soros first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 2 quarters.
  • George Soros's MoonLake Immunotherapeutics position peaked at $6.04M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Soros Fund Management's 13F filing for Q1 2024, filed 15 May 2024.